Pegylated (40kDa) interferon alfa-2A (Pegasys™) in new combination therapies:: A preliminary report of a randomized, multicenter efficacy and safety study.

被引：0
|
作者：
Di Bisceglie, AM
Bernstein, DE
Rustgi, VR
Gitlin, N
Jeffers, LJ
Simon, D
Pappas, SC
Campagna, J
机构：
[1] St Louis Univ, St Louis, MO 63103 USA
[2] NYU, Sch Med, Manhasset, NY USA
[3] Georgetown Univ, Fairfax, VA USA
[4] Atlanta Gastroenterol Assoc, Atlanta, GA USA
[5] Univ Miami, Sch Med, Miami, FL USA
[6] Jacobi Med Ctr, Bronx, NY USA
[7] Roche Lab Inc, Nutley, NJ USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1139
引用
收藏
页码：444A / 444A
页数：1
相关论文
共 50 条
  • [1] Pegylated (40 kDa) interferon alfa-2A (PEGASYS®) in new combination therapies:: A report of a randomized, multicenter efficacy and safety study
    Di Bisceglie, AM
    Bernstein, DE
    Rustgi, VR
    Gitlin, N
    Jeffers, LJ
    Simon, D
    Campagna, J
    Pappas, SC
    [J]. JOURNAL OF HEPATOLOGY, 2001, 34 : 143 - 143
  • [2] Characterization of pegylated (40kDa) interferon alfa-2A (Pegasys™) in the elderly.
    Martin, NE
    Modi, MW
    Reddy, KR
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [3] Pegylated (40KDA) interferon ALFA-2A (Pegasys™) is unaffected by renal impairment.
    Martin, P
    Mitra, S
    Farrington, K
    Martin, NE
    Modi, MW
    [J]. HEPATOLOGY, 2000, 32 (04) : 370A - 370A
  • [4] Clearance of pegylated (40KDA) interferon alfa-2a (Pegasys™) is primarily hepatic.
    Modi, MW
    Fulton, JS
    Buckmann, DK
    Wright, TL
    Moore, DJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 371A - 371A
  • [5] Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
    Fried, MW
    Shiffman, ML
    Reddy, RK
    Smith, C
    Marino, G
    Goncales, F
    Haeussinger, D
    Diago, M
    Carosi, G
    Zarski, JP
    Hoffman, J
    Yu, J
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A55 - A55
  • [6] Enhanced efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with interferon alfa-2A (Roferon-A™) for chronic hepatitis C in Blacks.
    Shiffman, ML
    Fromm, H
    Mills, P
    Moonka, DK
    Fried, MW
    Berg, C
    Sherman, M
    Smith, C
    Marsano, L
    Reddy, KR
    Brunda, MJ
    DePamphilis, J
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [7] Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil (CellCept®), amantadine, or amantadine plus ribavirin in patients that relapsed on Rebetron™ therapy:: A preliminary report of a randomized, multicenter efficacy and safety study
    Herrine, SK
    Brown, R
    Esposito, S
    Lok, A
    Galati, JS
    Bernstein, DE
    Campagna, J
    Pappas, SC
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A384 - A384
  • [8] 40 kDa peginterferon alfa-2a (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with HCV genotype 1:: A preliminary report of a comparative, multicenter, efficacy and safety study.
    Jeffers, LJ
    Cassidy, W
    Howell, C
    Reddy, KR
    Fallon, M
    Dragutsky, M
    Harb, GE
    Biran, T
    [J]. HEPATOLOGY, 2001, 34 (04) : 326A - 326A
  • [9] Improved work productivity, safety, and quality of life with pegylated (40KDA) interferon alfa-2a (Pegasys™) therapy in the treatment of chronic hepatitis C.
    Perrillo, RP
    Thuluvath, PJ
    Rothstein, K
    Alam, I
    Palmer, M
    Gordon, S
    Pappas, SC
    Wynohradnyk, L
    [J]. HEPATOLOGY, 2000, 32 (04) : 362A - 362A
  • [10] Pegylated (40kDa) interferon alfa-2a (pegasys™) is superior to interferon alfa-2a (roferon-A®) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584.
    Heathcote, EJ
    Balart, LA
    Shiffman, ML
    Pockros, PJ
    Lee, SS
    Reddy, KR
    Minuk, YG
    Bain, V
    Sherman, M
    Wright, TL
    Reindollar, RW
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 223A - 223A
12345